Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2360995 | 0.87 | NPC1 (0.45) | ALDH1A1NPC1LMNARAB9AKDM4E | |
| SCHEMBL8477927 | 0.85 | RAB9A (0.47) | ALDH1A1NPC1LMNARAB9AKDM4E | |
| SCHEMBL9528826 | 0.83 | KMT2A (0.40) | ALDH1A1NPC1LMNARAB9AKDM4E | |
| SCHEMBL18209763 | 0.83 | CYP1A2 (0.42) | ALDH1A1NPC1LMNARAB9AKDM4E | |
| SCHEMBL18209678 | 0.83 | RAB9A (0.42) | ALDH1A1NPC1LMNARAB9AKDM4E | |
| SCHEMBL6228921 | 0.80 | KDM4E (0.42) | ALDH1A1NPC1LMNARAB9AKDM4E | |
| SCHEMBL8827476 | 0.80 | RAB9A (0.45) | ALDH1A1NPC1LMNARAB9AKDM4E | |
| SCHEMBL1406834 | 0.80 | NPC1 (0.49) | ALDH1A1NPC1LMNARAB9AKDM4E | |
| SCHEMBL8573566 | 0.78 | RAB9A (0.50) | ALDH1A1NPC1LMNARAB9AKDM4E | |
| SCHEMBL4701434 | 0.76 | RAB9A (0.49) | ALDH1A1NPC1LMNARAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7118267-A | — | — | None | — | — | JP | disclosed |
| US-20240317767-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ASTRAZENECA AB (SE) | 2024-09-26 | — | — | US | disclosed |
| US-12024523-B2 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | ASTRAZENECA AB (SE) | 2024-07-02 | — | — | US | disclosed |
| US-20230219967-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ASTRAZENECA AB (SE) | 2023-07-13 | — | — | US | disclosed |
| US-11691978-B2 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | ASTRAZENECA AB (SE) | 2023-07-04 | — | — | US | disclosed |
| US-20210355127-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ASTRAZENECA AB (SE) | 2021-11-18 | — | — | US | disclosed |
| EP-3670499-B1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ASTRAZENECA AB (SE) | 2021-09-29 | — | — | EP | disclosed |
| US-11001589-B2 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | ASTRAZENECA AB (SE) | 2021-05-11 | — | — | US | disclosed |
| EP-3670499-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | Astrazeneca AB (SE) | 2020-06-24 | — | — | EP | disclosed |
| US-20200157113-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ASTRAZENECA AB (SE) | 2020-05-21 | — | — | US | disclosed |
| EP-0613896-A1 | Process for the preparation of sulfonylurea derivatives and intermediates for this process | LUCKY LTD. (KR) | 1994-09-07 | — | — | EP | disclosed |
| EP-0355385-B1 | SUBSTITUTED 4-SULPHONYLAMINO-2-AZINYL-1,2,4-TRIAZOL-3-ONES, PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES | BAYER AG (DE) | 1993-05-19 | — | — | EP | disclosed |
| US-5151514-A | Triazine substituted herbicides | BAYER AKTIENGESELLSCHAFT (DE) | 1992-09-29 | — | — | US | disclosed |
| US-5142060-A | Herbicidal substituted 4-sulphonylamino-2-azinyl-1,2,4-triazol-3-ones | BAYER AKTIENGESELLSCHAFT (DE) | 1992-08-25 | — | — | US | disclosed |
| US-5126454-A | PROCESS FOR THE PREPARATION OF SULPHONYLISOUREAS | BAYER AKTIENGESELLSCHAFT (DE) | 1992-06-30 | — | — | US | disclosed |
| US-5089627-A | Chemical intermediates therefor | BAYER AKTIENGESELLSCHAFT (DE) | 1992-02-18 | — | — | US | disclosed |
| US-5085687-A | HERBICIDAL SUBSTITUTED 4-SULPHONYLAMINO-2-AZINYL-1,2,4-TRIAZOL-3-ONES | BAYER AKTIENGESELLSCHAFT (DE) | 1992-02-04 | — | — | US | disclosed |
| EP-0416319-A2 | Process for the preparation of sulfonylisoureas | BAYER AG (DE) | 1991-03-13 | — | — | EP | disclosed |
| US-4988381-A | HERBICIDES, PLANT GROWTH REGULATORS | BAYER AKTIENGESELLSCHAFT (DE) | 1991-01-29 | — | — | US | disclosed |
| EP-0355385-A1 | Substituted 4-sulphonylamino-2-azinyl-1,2,4-triazol-3-ones, process and intermediates for their preparation and their use as herbicides | BAYER AG (DE) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157113-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, LIPG, ALOX15 | ALDH1A1 545/4885NPC1 2609/4885LMNA 1775/4885 |
| US-20210355127-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, LIPG, ALOX15 | ALDH1A1 545/4885NPC1 2609/4885LMNA 1775/4885 |
| US-11691978-B2 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | ALOX5, LIPG, ALOX15 | ALDH1A1 545/4885NPC1 2609/4885LMNA 1775/4885 |
| US-20230219967-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, LIPG, ALOX15 | ALDH1A1 545/4885NPC1 2609/4885LMNA 1775/4885 |
| US-20240317767-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, LIPG, ALOX15 | ALDH1A1 545/4885NPC1 2609/4885LMNA 1775/4885 |
| US-12024523-B2 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | ALOX5, LIPG, ALOX15 | ALDH1A1 545/4885NPC1 2609/4885LMNA 1775/4885 |
| US-11001589-B2 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | ALOX5, LIPG, ALOX15 | ALDH1A1 545/4885NPC1 2609/4885LMNA 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.